Related Experiment Video
Updated: Mar 29, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
How can we improve on the already impressive results in pediatric ALL?
1Royal Hospital for Sick Children, Edinburgh, UK.
Insights
Childhood acute lymphoblastic leukemia survival has dramatically improved, but intensified treatments cause significant toxicities. Research now focuses on personalized medicine using molecular markers and patient genetics to optimize therapy and reduce adverse events.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Biology
Background:
- Childhood acute lymphoblastic leukemia (ALL) has transitioned from a fatal diagnosis to a highly curable disease (>85% survival) over 70 years.
- Intensified treatment protocols have increased cure rates but also led to significant long-term toxicities and morbidities in survivors.
- Current research aims to refine treatment strategies by identifying sensitive biomarkers for disease response and patient susceptibility to toxicity.
Purpose of the Study:
- To review advancements in childhood acute lymphoblastic leukemia treatment, focusing on personalized medicine approaches.
- To highlight the importance of molecular markers for risk stratification and novel therapy development.
- To emphasize the role of patient-specific factors, such as pharmacogenomics, in managing treatment toxicity.
Main Methods:
- Review of historical treatment outcomes and current therapeutic strategies in pediatric acute lymphoblastic leukemia.
- Analysis of molecular markers for disease characterization, treatment response monitoring, and identification of therapeutic targets.
- Exploration of pharmacogenomic approaches for tailoring treatment based on individual genetic profiles.
Main Results:
- Significant progress in childhood acute lymphoblastic leukemia survival rates due to treatment intensification.
- Identification of molecular markers and clinical characteristics for risk-based treatment stratification.
- Growing understanding of patient susceptibility to treatment-related toxicities, paving the way for personalized interventions.
Conclusions:
- Personalized medicine, integrating molecular profiling and pharmacogenomics, is crucial for optimizing childhood acute lymphoblastic leukemia treatment.
- Future research and clinical trials must focus on developing targeted therapies and refining treatment intensity to improve outcomes while minimizing long-term toxicities.
- Ensuring timely access to novel, safe, and effective therapies through well-designed pediatric trials is paramount.
Abstract:
The past 70 years have seen childhood acute lymphoblastic leukemia move from a fatal disease with a survival of barely 4 months to a curable disease in >85% of patients. It has become clear that as treatment has intensified, more children are cured but at the expense of increased toxicity which for some can cause significant long-term morbidity and even mortality. The drive in more recent years has been to identify sensitive markers of disease and response to treatment to allow a reduction in therapy in those who do not require it and more intensive treatment in those who do. Clinical characteristics have been used to stratify patients into different risk groups and this, coupled with following response at a molecular level, has done much to tailor treatment to the patient. Considerable research has been focused on the molecular characteristics of the leukemia itself to elucidate the biologic mechanisms underlying both the disease and the comparative or absolute resistance of some types of leukemia. These molecular markers can also act as targets for novel therapies, which require newer trial methodologies to prove their utility. There has been less focus on the biology of the patient but it is clear that some patients are more susceptible to adverse events and toxicities than others. Through the use of pharmacogenomics, modification to therapy may be appropriate in certain patients based on their genetic profile. As novel therapies become available, suitable controlled trials in children are essential for their safe use in this population and will ensure that children are not denied timely access to advances in treatment.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...